However, although hepatic GPx activity was a tendency to decrease by NAC treatment in animals, expression levels of hepatic GPX1 and GPX4 were higher in mice and patients with NAFLD compared to those of controls in transcriptomic analyses. This evidence concerns the gene GPX1 and metabolic dysfunction-associated steatotic liver disease.